Skip to content
FloodGate Medical
Client spotlight

Ceribell

Clarity When It's Critial

Ceribell logo

About Us

Ceribell is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. Ceribell has developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, highly portable, and rapidly deployable hardware with sophisticated artificial intelligence (“AI”)-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. The Ceribell System is FDA 510(k) cleared for indicating suspected seizure activity and currently utilized in intensive care units and emergency rooms across the U.S. Ceribell is headquartered in Sunnyvale, California. Our mission is to establish the Ceribell System as the standard of care for EEG in the acute care setting and help clinicians save patient lives.

Video

Look at the Leaders of Ceribell

Jane Chao, PHD

CEO, Co-Founder, and Director

Raymond Woo, PHD

Chief Technology Officer

Scott Blumberg

Chief Financial Officer

Provider Experiences with Ceribell

Paul Vespa shares his experience with Ceribell EEG

Paul

“Ceribell, is easy to use, easy to apply, and would be greatly utilized in emergency departments or small hospitals where they just don’t have the available services to rapidly assess the patient.”

Laleh Gharahbaghian shares her experience with Ceribell EEG

Laleh

“They are eager to use it [Ceribell] because they understand its effect and impact and the data that they can obtain from it is quite easily and quite quickly and quite accurate.”

Mary Kay Bader shares her experience with Ceribell EEG

Emily

“The Ceribell EEG technologies have improved our ability to detect and treat seizures… it’s readily available, it’s in the ICU, it’s in the emergency department.”

Company Spotlight Video

Opportunities with Treace Medical

News and Stories

Medtech Leader Erica Rogers Joins Ceribell Board of Directors

SUNNYVALE, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) — CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell” or the “Company”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced the appointment of Erica Rogers to its Board of Directors. Ms. Rogers brings over three decades of experience leading high-growth, innovative medical device companies to Ceribell’s Board as the Company executes on its mission to expand patient access to timely brain monitoring in the acute care setting.

Ceribell Reports Second Quarter 2025 Financial Results

SUNNYVALE, Calif., Aug. 05, 2025 (GLOBE NEWSWIRE) — CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial results for the quarter ended June 30, 2025.

Ceribell to Participate in the Canaccord Genuity 45th Annual Growth Conference

SUNNYVALE, Calif., July 29, 2025 (GLOBE NEWSWIRE) — CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Jane Chao, Ph.D., CEO and Co-founder, will present at the upcoming Canaccord Genuity 45th Annual Growth Conference. The presentation will take place on Tuesday, August 12, 2025, at 11:00 a.m. Pacific Standard Time / 2:00 p.m. Eastern Standard Time.

25+ years of pattern recognition in MedTech talent
The quality of a company's managers has an outsized impact on performance, development, engagement and retention.

Interested in a role at Ceribell?

Tell us. If FloodGate is running a search there, or one like it, a Talent Advisor who knows the company will be in touch.